At #SABCS24, Steffi Hartmann presented findings from the AXSANA registry trial (NCT04373655), the largest prospective study evaluating the diagnostic performance of axillary ultrasound (AUS) in initially node-positive breast cancer patients post-neoadjuvant chemotherapy (NACT).
Key takeaways:
AUS alone cannot reliably determine nodal status post-NACT.
False-negative rates were substantial, even in patients with factors linked to lower risk.
Surgical overtreatment could affect 35.8% of patients with suspicious AUS, particularly those with HER2+ or triple-negative subtypes.
Positive and negative predictive values varied significantly by tumor subtype.
These results challenge the role of AUS in guiding axillary surgery decisions and emphasize the need for a nuanced approach tailored to tumor biology.
Explore more about the study: https://lnkd.in/eBAPrtSA
Kudos to Steffi Hartmann and the AXSANA Study Group for their important contribution!
